DEVELOPMENT AND VALIDATION OF STEROID AND OTHER ASSAYS BY LIQUID CHROMATOGRAPHY

类固醇和其他液相色谱分析方法的开发和验证

• 批准号: 8174528
• 负责人: CHRISTINA C. WANG
• 金额: $ 7.8万
• 依托单位: LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-12-01 至 2010-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8174528
• 关键词: Androgens; Biological Assay; Blood; Blood Volume; Child; Clinical; Clinical Research; Computer Retrieval of Information on Scientific Projects Database; Detection; Development; Estradiol; Funding; Grant; Hormones; Human; Immunoassay; Institution; Laboratories; Liquid Chromatography; Measurement; Measures; Methods; Monitor; Ovary; Patients; Physicians; Postmenopause; Precocious Puberty; Research; Research Personnel; Resources; Sampling; Serum; Source; Steroids; Testing; Testosterone; United States National Institutes of Health; Validation; Woman; liquid chromatography mass spectrometry; steroid hormone; tandem mass spectrometry

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. At present, current immunoassay methods cannot accurately or precisely measure low levels of steroid hormones in humans. As a result, below a certain lower limit of detection using conventional laboratory methods, testing for steroid levels in the blood often yields little clinically useful information. Postmenopausal women and women who have had their ovaries removed who are being studied for androgen replacement need an accurate method of monitoring treatment. Children who have clinical signs of precocious puberty need a method of measuring low testosterone or estradiol levels that may support clinical findings and are different from the levels of normal children. However, levels in normal children cannot be accurately measured because of the inherent problems of the current assay methods Tandem mass spectrometry (aka liquid chromatography-mass spectrometry-mass spectromery or LCMSMS) has the potential to sensitively, accurately, and precisely measure low levels of hormones. The Harbor-UCLA General Clinical Research Center would like to validate measurement of androgens, estradiol, steroid metabolites, and synthetic steroid compounds using tandem mass spectrometry. In order to validate measurements using tandem mass spectrometry, samples of human serum are needed. We propose to use leftover blood from patients whose clinical information is known and are having clinically indicated laboratory testing as ordered by his or her regular physicians. The volume of blood needed from each sample is approximately 200 ul.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 目前，目前的免疫测定方法不能准确或精确地测量人体中低水平的类固醇激素。 因此，在使用传统实验室方法的一定检测下限以下，血液中类固醇水平的检测通常不会产生多少临床有用的信息。 绝经后妇女和正在接受雄激素替代治疗的卵巢切除妇女需要一种准确的监测治疗方法。 有性早熟临床症状的儿童需要一种测量低睾酮或雌二醇水平的方法，这种方法可能支持临床发现，并且与正常儿童的水平不同。 然而，由于目前测定方法的固有问题，不能准确测量正常儿童的水平 串联质谱法（又名液相色谱-质谱-质谱或LCMSMS）具有灵敏，准确和精确测量低水平激素的潜力。 Harbor-UCLA综合临床研究中心希望验证使用串联质谱法测量雄激素、雌二醇、类固醇代谢物和合成类固醇化合物。 为了验证使用串联质谱法的测量，需要人血清样品。 我们建议使用患者的剩余血液，这些患者的临床信息是已知的，并且正在按照其常规医生的要求进行临床指示的实验室检测。 每个样本所需的血液体积约为200 μ l。